Shire's stock surges after ADHD drug trial meets key endpoints - MarketWatch

Shire's stock surges after ADHD drug trial meets key endpoints MarketWatch Shares of Shire PLC SHPG, +5.65% surged 3.5% in premarket trade Wednesday, after the drug maker said a trial of its treatment for attention-deficit/hyperactivity disorder (ADHD) met its primary efficacy and safety endpoints. The secondary endpoint of ... and more »

from Health - Google News http://news.google.com/news/url?sa=t&fd=R&ct2=us&usg=AFQjCNF_-dvmTYKOu6JGueFIISJRhJCvbw&clid=c3a7d30bb8a4878e06b80cf16b898331&cid=52779143733902&ei=PKp0V-jXD5bF3QHej6jADQ&url=http://www.marketwatch.com/story/shires-stock-surges-after-adhd-drug-trial-meets-key-endpoints-2016-06-29
via IFTTT